Gyre Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Gyre Therapeutics has a total shareholder equity of $93.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $120.9M and $27.6M respectively. Gyre Therapeutics's EBIT is $18.9M making its interest coverage ratio -14.7. It has cash and short-term investments of $25.1M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -14.7x |
| Cash | US$25.10m |
| Equity | US$93.35m |
| Total liabilities | US$27.58m |
| Total assets | US$120.93m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: GYRE's short term assets ($53.5M) exceed its short term liabilities ($15.6M).
Long Term Liabilities: GYRE's short term assets ($53.5M) exceed its long term liabilities ($12.0M).
Debt to Equity History and Analysis
Debt Level: GYRE is debt free.
Reducing Debt: GYRE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable GYRE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: GYRE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.6% per year.